Antibacterial Resistance Leadership Group 2.0: Back to Business

Henry F Chambers; Scott R Evans; Robin Patel; Heather R Cross; Anthony D Harris; Yohei Doi; Helen W Boucher; David van Duin; Ephraim L Tsalik; Thomas L Holland; Melinda M Pettigrew; Pranita D Tamma; Kathryn R Hodges; Maria Souli; Vance G Fowler

doi:10.1093/cid/ciab141

Antibacterial Resistance Leadership Group 2.0: Back to Business

Clin Infect Dis. 2021 Aug 16;73(4):730-739. doi: 10.1093/cid/ciab141.

Authors

Henry F Chambers¹, Scott R Evans², Robin Patel³, Heather R Cross⁴, Anthony D Harris⁵, Yohei Doi^{6

7}, Helen W Boucher⁸, David van Duin⁹, Ephraim L Tsalik^{10

11}, Thomas L Holland^{4

11}, Melinda M Pettigrew¹², Pranita D Tamma¹³, Kathryn R Hodges⁴, Maria Souli⁴, Vance G Fowler^{4

11}

Affiliations

¹ Division of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, California, USA.
² Biostatistics Center, Department of Biostatics and Bioinformatics, Milken Institute School of Public Health, George Washington University, Washington, D.C., USA.
³ Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology; Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
⁴ Duke Clinical Research Institute, Durham, North Carolina, USA.
⁵ Department of Epidemiology and Public Health University of Maryland School of Medicine; Baltimore, Maryland, USA.
⁶ Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
⁷ Department of Microbiology and Infectious Diseases, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
⁸ Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, Massachusetts, USA.
⁹ Division of Infectious Diseases, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.
¹⁰ Emergency Medicine Service, Durham VA Health Care System, Durham, North Carolina, USA.
¹¹ Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
¹² Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, USA.
¹³ Division of Infectious Diseases, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Abstract

In December 2019, the Antibacterial Resistance Leadership Group (ARLG) was awarded funding for another 7-year cycle to support a clinical research network on antibacterial resistance. ARLG 2.0 has 3 overarching research priorities: infections caused by antibiotic-resistant (AR) gram-negative bacteria, infections caused by AR gram-positive bacteria, and diagnostic tests to optimize use of antibiotics. To support the next generation of AR researchers, the ARLG offers 3 mentoring opportunities: the ARLG Fellowship, Early Stage Investigator seed grants, and the Trialists in Training Program. The purpose of this article is to update the scientific community on the progress made in the original funding period and to encourage submission of clinical research that addresses 1 or more of the research priority areas of ARLG 2.0.

Keywords: Antibacterial Resistance Leadership Group; clinical research; mentoring.

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Anti-Bacterial Agents / pharmacology
Anti-Bacterial Agents / therapeutic use
Drug Resistance, Bacterial*
Gram-Negative Bacteria
Gram-Positive Bacteria
Leadership*

Substances

Anti-Bacterial Agents

Abstract

Publication types

MeSH terms

Substances

Grants and funding